158 related articles for article (PubMed ID: 38076413)
21. Leveraging advances in diabetes technologies in primary care: a narrative review.
Bode B; King A; Russell-Jones D; Billings LK
Ann Med; 2021 Dec; 53(1):805-816. PubMed ID: 34184589
[TBL] [Abstract][Full Text] [Related]
22. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
23. Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial.
Nilsson M; Jensen N; Gejl M; Bergmann ML; Storgaard H; Zander M; Miskowiak K; Rungby J
Diabetologia; 2019 Oct; 62(10):1948-1958. PubMed ID: 31367958
[TBL] [Abstract][Full Text] [Related]
24. The incidence of severe hypoglycaemia in pregnant women with type 1 diabetes mellitus can be reduced with unchanged HbA1c levels and pregnancy outcomes in a routine care setting.
Ringholm L; Secher AL; Pedersen-Bjergaard U; Thorsteinsson B; Andersen HU; Damm P; Mathiesen ER
Diabetes Res Clin Pract; 2013 Aug; 101(2):123-30. PubMed ID: 23820486
[TBL] [Abstract][Full Text] [Related]
25. High intensity interval training as a novel treatment for impaired awareness of hypoglycaemia in people with type 1 diabetes (HIT4HYPOS): a randomised parallel-group study.
Farrell CM; McNeilly AD; Hapca S; Fournier PA; Jones TW; Facchinetti A; Cappon G; West DJ; McCrimmon RJ
Diabetologia; 2024 Feb; 67(2):392-402. PubMed ID: 38010533
[TBL] [Abstract][Full Text] [Related]
26. Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon.
Thieu VT; Mitchell BD; Varnado OJ; Frier BM
Diabetes Obes Metab; 2020 Apr; 22(4):469-479. PubMed ID: 31820562
[TBL] [Abstract][Full Text] [Related]
27. Hypoglycaemia and its management in primary care setting.
Ibrahim M; Baker J; Cahn A; Eckel RH; El Sayed NA; Fischl AH; Gaede P; Leslie RD; Pieralice S; Tuccinardi D; Pozzilli P; Richelsen B; Roitman E; Standl E; Toledano Y; Tuomilehto J; Weber SL; Umpierrez GE
Diabetes Metab Res Rev; 2020 Nov; 36(8):e3332. PubMed ID: 32343474
[TBL] [Abstract][Full Text] [Related]
28. A pilot study using flash continuous glucose monitoring in patients with type-2 diabetes on multiple anti-diabetic agents during Ramadan.
Bashir M; Elhadd T; Ali H; Baagar K; Abdel Hakam IA; Al-Mohanadi DHS; Naem E; Al Abdulla A; Mohammed K; Abou-Samra AB
Diabetes Metab Syndr; 2018 Nov; 12(6):965-968. PubMed ID: 29895446
[TBL] [Abstract][Full Text] [Related]
29. Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials.
Kautzky-Willer A; Kosi L; Lin J; Mihaljevic R
Diabetes Obes Metab; 2015 Jun; 17(6):533-540. PubMed ID: 25678212
[TBL] [Abstract][Full Text] [Related]
30. Intensification of Diabetes Medications at Hospital Discharge and Clinical Outcomes in Older Adults in the Veterans Administration Health System.
Anderson TS; Lee AK; Jing B; Lee S; Herzig SJ; Boscardin WJ; Fung K; Rizzo A; Steinman MA
JAMA Netw Open; 2021 Oct; 4(10):e2128998. PubMed ID: 34673963
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
Matsuda E; Brennan P
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
[TBL] [Abstract][Full Text] [Related]
33. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
34. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.
Chelliah A; Burge MR
Drugs Aging; 2004; 21(8):511-30. PubMed ID: 15182216
[TBL] [Abstract][Full Text] [Related]
35. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
[TBL] [Abstract][Full Text] [Related]
37. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
